What To Know
- Giarracco combines this expertise with start-up experience as chief operations officer at SeaStar Medical and as a lead investor and board member at early-stage healthcare technology companies.
- “As a Noninvasix founder and practicing anesthesiologist, I am excited about our future and the opportunity to make a significant impact on this major healthcare challenge.
Noninvasix reported today that David J. Giarracco has been appointed the new CEO of the company. A veteran medical device executive with relevant critical care market experience, Giarracco will advance the commercialization of the only non-invasive patient monitoring device designed for earlier detection of life-threatening sepsis so it can be treated to improve patient outcomes.
Dave is the right leader at the right time for Noninvasix,” said Tom Luby, Ph.D., Director of Texas Medical Center Innovation Venture Fund. “He has a deep understanding of launching new platform technologies that make a critical difference in patient safety and clinical outcomes while reducing overall healthcare costs.”
Giarracco has extensive experience in the launch and global commercialization of novel patient-monitoring technologies in both hospital and home care settings. In leadership roles at Medtronic and Covidien, he successfully scaled organizations to exceed business plans by strategically developing markets, addressing commercial structure, and creating clinically focused, solution-selling organizations. Giarracco combines this expertise with start-up experience as chief operations officer at SeaStar Medical and as a lead investor and board member at early-stage healthcare technology companies.
“Dave will play an essential role in helping refine our strategy and drive product development activity to realize our mission of better detecting and monitoring sepsis,” said Dr. Donald Prough, Rebecca Terry White Distinguished Professor and Chairman of the Department of Anesthesia at the University of Texas Medical Branch. “As a Noninvasix founder and practicing anesthesiologist, I am excited about our future and the opportunity to make a significant impact on this major healthcare challenge.”
“Prevention and control strategies for sepsis infections are urgently needed,” said Giarracco. “We need new, non-invasive approaches for early diagnosis to reduce complications and save lives. Noninvasix technology promises to make a major difference in patient care, reduce healthcare costs and have wider applications beyond sepsis.”
Giarracco received his Bachelor of Science in Biomedical Engineering from The Johns Hopkins University and his Master of Arts in Biomedical Engineering from The Johns Hopkins School of Medicine. He brings more than 25 years of medical technology experience as an engineer, commercial leader, and early-stage investor in innovative, category-defining technologies.